Literature DB >> 27919887

Genotyping and Prevalence of Pyrazinamide- and Moxifloxacin-Resistant Tuberculosis in China, 2000 to 2010.

Yu Pang1, Zhijian Zhang2, Yufeng Wang1, Shengfen Wang1, Yuanyuan Song1, Bing Zhao1, Yang Zhou1, Xichao Ou1, Qiang Li1, Hui Xia1, Yang Zheng1, Xiangqun Fang3, Yanlin Zhao4.   

Abstract

We investigated the prevalence, trends, and risk factors for pyrazinamide (PZA) and moxifloxacin (MOX) resistance among tuberculosis (TB) cases in China and also analyzed the population structure of Mycobacterium tuberculosis strains. All the M. tuberculosis strains enrolled in this study were collected from the national TB prevalence surveys. Each strain was genotyped by analyzing the regions of RD105 and IS6110 in the NTF region. The Bactec MGIT 960 system was used to detect the drug susceptibility of M. tuberculosis isolates to PZA and MOX. Based on the genotyping results, 241 (66.4%) strains were classified as Beijing genotype in 2000, which was significantly lower than in 2010 (76.2%, P < 0.01). The proportion of the modern Beijing genotype increased significantly from 49.6% in 2000 to 68.1% in 2010 (P < 0.01), while no significant difference was observed in the rate of ancient Beijing genotype between 2000 and 2010 (P = 0.676). In addition, we found that the proportion of PZA resistance in 2010 (15.0%) was significantly higher than that in 2000 (9.6%, P = 0.04). For MOX, there were more MOX-resistant isolates detected in 2010 (7.7%) than in 2000 (3.0%). In conclusion, our data demonstrate that the Beijing genotype was the predominant M. tuberculosis lineage during the past decade. The proportion of Beijing genotype isolates significantly increased from 2000 to 2010, largely due to an increase in the modern Beijing sublineage. In addition, resistance to PZA and MOX increased significantly in China between 2000 and 2010.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  Beijing genotype; China; Mycobacterium tuberculosis; moxifloxacin; pyrazinamide

Mesh:

Substances:

Year:  2017        PMID: 27919887      PMCID: PMC5278687          DOI: 10.1128/AAC.02170-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  38 in total

Review 1.  Possible underlying mechanisms for successful emergence of the Mycobacterium tuberculosis Beijing genotype strains.

Authors:  Ida Parwati; Reinout van Crevel; Dick van Soolingen
Journal:  Lancet Infect Dis       Date:  2010-02       Impact factor: 25.071

2.  Genetic profile of tuberculosis among the migrant population in Fujian Province, China.

Authors:  Q-F Liang; Y Pang; Q-Y Chen; S-F Lin; J Lin; Y Zhao; S-Z Wei; J-F Zheng; S-H Zheng
Journal:  Int J Tuberc Lung Dis       Date:  2013-05       Impact factor: 2.373

Review 3.  Mechanisms of Pyrazinamide Action and Resistance.

Authors:  Ying Zhang; Wanliang Shi; Wenhong Zhang; Denis Mitchison
Journal:  Microbiol Spectr       Date:  2014-08

4.  A novel method based on high resolution melting (HRM) analysis for MIRU-VNTR genotyping of Mycobacterium tuberculosis.

Authors:  Yu Pang; Yang Zhou; Shengfen Wang; Jie Lu; Bing Lu; Guangxue He; Lixia Wang; Yanlin Zhao
Journal:  J Microbiol Methods       Date:  2011-06-13       Impact factor: 2.363

5.  Serum drug concentrations predictive of pulmonary tuberculosis outcomes.

Authors:  Jotam G Pasipanodya; Helen McIlleron; André Burger; Peter A Wash; Peter Smith; Tawanda Gumbo
Journal:  J Infect Dis       Date:  2013-07-29       Impact factor: 5.226

6.  Validation of pncA gene sequencing in combination with the mycobacterial growth indicator tube method to test susceptibility of Mycobacterium tuberculosis to pyrazinamide.

Authors:  Sami O Simons; Jakko van Ingen; Tridia van der Laan; Arnout Mulder; P N Richard Dekhuijzen; Martin J Boeree; Dick van Soolingen
Journal:  J Clin Microbiol       Date:  2011-11-16       Impact factor: 5.948

7.  Mycobacterium tuberculosis Beijing strains favor transmission but not drug resistance in China.

Authors:  Chongguang Yang; Tao Luo; Guomei Sun; Ke Qiao; Gang Sun; Kathryn DeRiemer; Jian Mei; Qian Gao
Journal:  Clin Infect Dis       Date:  2012-08-03       Impact factor: 9.079

8.  Prevalence and molecular characteristics of drug-resistant Mycobacterium tuberculosis in Hunan, China.

Authors:  Li-li Zhao; Yan Chen; Zhong-nan Chen; Hai-can Liu; Pei-lei Hu; Qing Sun; Xiu-qin Zhao; Yi Jiang; Gui-lian Li; Yun-hong Tan; Kang-lin Wan
Journal:  Antimicrob Agents Chemother       Date:  2014-04-14       Impact factor: 5.191

9.  Controlled trial of four thrice-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis.

Authors: 
Journal:  Lancet       Date:  1981-01-24       Impact factor: 79.321

10.  Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project.

Authors:  Matteo Zignol; Anna S Dean; Natavan Alikhanova; Sönke Andres; Andrea Maurizio Cabibbe; Daniela Maria Cirillo; Andrei Dadu; Andries Dreyer; Michèle Driesen; Christopher Gilpin; Rumina Hasan; Zahra Hasan; Sven Hoffner; Ashaque Husain; Alamdar Hussain; Nazir Ismail; Mostofa Kamal; Mikael Mansjö; Lindiwe Mvusi; Stefan Niemann; Shaheed V Omar; Ejaz Qadeer; Leen Rigouts; Sabine Ruesch-Gerdes; Marco Schito; Mehriban Seyfaddinova; Alena Skrahina; Sabira Tahseen; William A Wells; Ya Diul Mukadi; Michael Kimerling; Katherine Floyd; Karin Weyer; Mario C Raviglione
Journal:  Lancet Infect Dis       Date:  2016-07-07       Impact factor: 25.071

View more
  7 in total

1.  In Vitro Drug Susceptibility of Bedaquiline, Delamanid, Linezolid, Clofazimine, Moxifloxacin, and Gatifloxacin against Extensively Drug-Resistant Tuberculosis in Beijing, China.

Authors:  Yu Pang; Zhaojing Zong; Fengmin Huo; Wei Jing; Yifeng Ma; Lingling Dong; Yunxu Li; Liping Zhao; Yuhong Fu; Hairong Huang
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

2.  Clinical Impact of Rapid Drug Susceptibility Testing to Accompany Fluoroquinolone-Containing Universal Tuberculosis Regimens: A Markov Model.

Authors:  Emily A Kendall; Shelly Malhotra; Sarah Cook-Scalise; David W Dowdy; Claudia M Denkinger
Journal:  Clin Infect Dis       Date:  2020-12-31       Impact factor: 9.079

3.  Prevalence of extensively drug-resistant tuberculosis in a Chinese multidrug-resistant TB cohort after redefinition.

Authors:  Cong Yao; Haiping Guo; Qiang Li; Xuxia Zhang; Yuanyuan Shang; Tongxin Li; Yufeng Wang; Zhongtan Xue; Lu Wang; Liang Li; Yu Pang
Journal:  Antimicrob Resist Infect Control       Date:  2021-08-26       Impact factor: 4.887

4.  A 10-Year Comparative Analysis Shows that Increasing Prevalence of Rifampin-Resistant Mycobacterium tuberculosis in China Is Associated with the Transmission of Strains Harboring Compensatory Mutations.

Authors:  Fengmin Huo; Jingjing Luo; Jin Shi; Zhaojing Zong; Wei Jing; Wenzhu Dong; Lingling Dong; Yifeng Ma; Qian Liang; Yuanyuan Shang; Hairong Huang; Yu Pang
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

5.  Relapse Versus Reinfection of Recurrent Tuberculosis Patients in a National Tuberculosis Specialized Hospital in Beijing, China.

Authors:  Zhaojing Zong; Fengmin Huo; Jin Shi; Wei Jing; Yifeng Ma; Qian Liang; Guanglu Jiang; Guangming Dai; Hairong Huang; Yu Pang
Journal:  Front Microbiol       Date:  2018-08-14       Impact factor: 5.640

6.  Strong Increase in Moxifloxacin Resistance Rate among Multidrug-Resistant Mycobacterium tuberculosis Isolates in China, 2007 to 2013.

Authors:  Hui Xia; Yang Zheng; Dongxin Liu; Shengfen Wang; WenCong He; Bing Zhao; Yuanyuan Song; Xichao Ou; Yang Zhou; Susan van den Hof; Frank Cobelens; YanLin Zhao
Journal:  Microbiol Spectr       Date:  2021-12-01

7.  Distinguishing Relapse From Reinfection With Whole-Genome Sequencing in Recurrent Pulmonary Tuberculosis: A Retrospective Cohort Study in Beijing, China.

Authors:  Jian Du; Qing Li; Min Liu; Yufeng Wang; Zhongtan Xue; Fengmin Huo; Xuxia Zhang; Yuanyuan Shang; Shanshan Li; Hairong Huang; Yu Pang
Journal:  Front Microbiol       Date:  2021-12-08       Impact factor: 5.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.